Emergency use of COVID-19 vaccines recommended by the World Health Organization (WHO) as of June 2021

Abstract

vaccine research, mRNA, adenoviral vectors, inactivated viruses, recombinant proteins In December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the outbreak of coronavirus disease 2019 , and the resulting pandemic has caused widespread health problems and social and economic disruption. Thus far in 2021, more than 4 million people worldwide have died from COVID-19, so safe and efficacious vaccines are urgently needed to restore normal economic and social activities. According to the official guidance documents of the World Health Organization (WHO), vaccines based on four major strategies including mRNA, adenoviral vectors, inactivated viruses, and recombinant proteins have entered the stage of emergency use authorization and pre-certification evaluation. The current review summarizes these vaccines and it looks ahead to the development of additional COVID-19 vaccines in the future.

COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status

“…Predefined type of vaccine in the current study was based on the authorized vaccines for emergency use in China as of 15 January 2022, including Inactivated SARS-CoV-2 Vaccine (CoronaVac from Sinovac, COVILO from Sinopharm/BIBP or Sinopharm/WIBP), Adenovirus-vectored vaccine (Convidecia from CanSinoBIO), and recombinant Novel Coronavirus Vaccine (Zhifei Longcom) [ 20 ].…”

Immediate Hypersensitivity Reactions Induced by COVID-19 Vaccines: Current Trends, Potential Mechanisms and Prevention Strategies

“…The administration of vaccines has successfully reduced the morbidity and mortality of COVID-19 [ 2 , 3 , 4 , 5 ]. According to the World Health Organization [ 6 ], the increasing availability and utilization of vaccines effectively protects people from the disease severity [ 7 , 8 , 9 ]. Currently, four classes of vaccines against COVID-19 are available.…”

Call for a Global Vaccine Plan to Combat Current and Future Pandemics: One for ALL and ALL for One

“…Still, when looking at the bigger picture concerning how many dollars were spent in other areas, this amount appeared to be minuscule, citing how the USA initially paid not enough healthcare dollars in vaccine procurement [8]. Many developing countries relied on the combined global effort through GAVI to guarantee at least 20% of needed vaccines for each country so frontline workers and high risk populations could be vaccinated [9]. The COVAX was launched in April 2020 to bring the private sector, nonprofit organizations, and government together to provide equitable solutions and access to COVID-19 vaccines, diagnostics, and therapeutics, offering hope to developing countries with access to vaccines, regardless of their financial capacities.…”

“…Their goal is to coordinate with GAVI, WHO, Coalition for Epidemic Preparedness Innovations (CEPI), and vaccine alliance to coordinate with the manufacturers, negotiate prices, secure vaccines, and provide equal access to participating countries. Their goal is to have 2 billion vaccines by the end of 2021 and provide vaccines to high-risk populations and frontline workers [9]. The fundamental goal of GAVI and COVAX is to guarantee that the vaccine is accessible to the 92 low-and middle-income countries that cannot afford to vaccinate their people [9].…”

“…Their goal is to have 2 billion vaccines by the end of 2021 and provide vaccines to high-risk populations and frontline workers [9]. The fundamental goal of GAVI and COVAX is to guarantee that the vaccine is accessible to the 92 low-and middle-income countries that cannot afford to vaccinate their people [9].…”